Women and Heart Disease: What Makes Cardiovascular Risk Different

Women and Heart Disease: What Makes Cardiovascular Risk Different

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief

Heart disease is the leading cause of death in women in the United States. In 2023, 304,970 American women died of it — about one in five female deaths, more than from breast cancer, lung cancer, and chronic respiratory disease combined. (1) Yet most cardiovascular research has been built primarily from male populations. The diagnostic frameworks and prevention guidelines derived from that evidence work less well when applied to women, with measurable consequences.

This article is the foundation for the series. Women’s cardiovascular biology shares the architecture of men’s but differs in specific ways that matter clinically — smaller coronary arteries, distinct plaque biology, a larger role for microvascular disease, and a presentation pattern broader than the textbook image. The articles that follow translate this foundation into the specific questions women face: symptoms, pregnancy, contraception, menopause, hormone therapy, and the conditions and syndromes that disproportionately affect women’s hearts.

The Scale

Cardiovascular disease has historically received less public attention than breast cancer despite causing more female deaths. The disparity in attention is not a small thing. It has shaped what women are screened for, what conversations happen in routine visits, and what symptoms get taken seriously when they occur.

In the United States, women’s cardiovascular mortality was higher than men’s in absolute numbers from 1984 through 2012. (1,2) That pattern reversed in 2013 as women’s mortality declined more rapidly through the early 2000s. The reversal in absolute numbers reflects real progress, not a decline in importance. Cardiovascular disease remains the leading cause of death in women, and the declines have been uneven — concentrated in older women, more modest in women under 55, and in some subgroup analyses stagnant or rising for certain cardiovascular conditions. (1,2) Mortality also declined less rapidly during the COVID-19 years, with partial recovery in 2023.

Lifetime risk is meaningful at every adult age. In Framingham Heart Study data, a woman at age 40 has approximately a 32 percent lifetime risk of developing coronary heart disease, compared with approximately 49 percent for a man at age 40. (7) Lower than for men. Not low. One in three women alive at 40 will develop coronary heart disease over her remaining lifetime.

The Research Gap

Most of cardiovascular medicine’s foundational evidence was built from research in men. The original Framingham cohort enrolled both sexes, but the major outcome trials of the late twentieth century enrolled predominantly male populations. The Scott analysis of FDA cardiovascular drug approvals across 2005 to 2015 — a period after the field had formally recognized the underrepresentation problem and committed to fixing it — found women constituted 36 percent of participants. (6) Women’s participation was reasonable in trials for atrial fibrillation, hypertension, and pulmonary arterial hypertension. Underrepresentation concentrated specifically in coronary artery disease, acute coronary syndrome, and heart failure trials.

The consequence is not that current cardiovascular treatments fail in women. Most cardiovascular treatments show broadly consistent benefit across sexes. The consequence is structural. Several features of women’s cardiovascular biology — coronary microvascular disease, plaque erosion mechanisms, spontaneous coronary artery dissection, the cardiovascular implications of pregnancy complications — were systematically under-studied during the period when standard clinical pathways were built. Those pathways were calibrated to the disease mechanisms most easily studied in the populations most easily enrolled.

The field is correcting. Major society guidelines now incorporate sex-specific recommendations more explicitly. Dedicated research programs — the Women’s Ischemia Syndrome Evaluation (WISE), the iSCAD international SCAD registry, the INOCA-International network — have produced the evidence earlier guidelines lacked. The 2021 American Heart Association scientific statement on adverse pregnancy outcomes and the 2020 statement on menopause and cardiovascular disease both exist because the conversations they describe were not happening enough in routine care. The current task is integrating that knowledge into what actually happens in the exam room.

How the Biology Differs

Three biological differences shape how cardiovascular disease develops, presents, and is detected in women. None means women have a categorically different cardiovascular system. Each shifts the distribution of disease in ways that have clinical consequences.

Coronary Artery Size

Women’s coronary arteries are smaller than men’s even after correction for body size.

In a foundational angiographic study of normal coronary anatomy, epicardial coronary diameter was approximately 9 percent smaller in women than in men after normalization for body surface area. (3) Intravascular ultrasound studies confirmed that left main and proximal left anterior descending dimensions are smaller in women independent of body size, indicating an intrinsic sex effect rather than a body-size effect alone. (8)

Smaller arteries are more difficult to image and more difficult to instrument during catheter-based procedures. They also accommodate less reserve before a given plaque produces critical narrowing. This is part of why some of the worse procedural outcomes historically observed in women appear to be at least partially attributable to coronary size differences rather than to differences in disease severity. (2,8) It is a normal sex-based difference that affects imaging, procedural risk, and how the same plaque presents clinically.

Plaque Biology

The classical mechanism of a heart attack is plaque rupture: a fatty plaque with a thin protective cap breaks open, blood meets the exposed core, a clot forms, and an artery occludes. This is the mechanism most often pictured when a heart attack is described. It accounts for the majority of fatal events in men.

A second mechanism — plaque erosion — contributes proportionally more in women. In erosion, the smooth inner lining of the artery wears away without the underlying plaque rupturing. The clot forms over a damaged surface rather than over a torn-open core. The underlying plaque has a different composition: less lipid, more fibrous material, less inflammatory activity.

The 2016 American Heart Association scientific statement on acute myocardial infarction in women quantified the distribution. Plaque rupture is responsible for approximately 76 percent of fatal heart attacks in men but only 55 percent in women. (2) In autopsy series, erosion is the underlying substrate in approximately 37 percent of women versus 19 percent of men, and the erosion share rises further in younger women. (2)

The two mechanisms differ in angiographic appearance, in the imaging modalities best suited to detect them, in their response to specific therapies, and in their long-term recurrence patterns. Diagnostic and treatment pathways calibrated primarily to rupture biology can underperform in disease driven by erosion.

The Microvasculature

The epicardial coronary arteries visible on standard angiography are only the proximal portion of the coronary circulation. Downstream lies the coronary microvasculature: arterioles, capillaries, and venules that distribute blood through the heart muscle. Conventional angiography maps the highway system. It does not see the neighborhood streets where most of the actual traffic distribution occurs. The microvasculature sits below the resolution of conventional angiography and can be deeply dysfunctional in a heart whose epicardial arteries look normal.

This is not a limitation of angiography as a test. Angiography remains an essential and highly effective tool for diagnosing obstructive coronary disease. The limitation is specific to disease below the imaging resolution — and that limitation matters disproportionately for women, in whom microvascular contribution to ischemic disease is more frequently identified than in men.

The Women’s Ischemia Syndrome Evaluation (WISE) study — a National Heart, Lung, and Blood Institute–sponsored prospective cohort of 936 women referred for clinically indicated coronary angiography because of suspected ischemia — quantified the scale. Only 39 percent of the women had obstructive coronary artery disease defined as more than 50 percent stenosis on angiography. (4) In a WISE subgroup of 159 women studied with intracoronary adenosine, 47 percent of those with chest pain and nonobstructive coronary arteries had reduced coronary flow reserve consistent with microvascular dysfunction. (4)

The majority of women with chest pain serious enough to prompt coronary angiography did not have the obstructive disease the test was designed to find. A substantial share of those women had microvascular disease the test could not detect.

The 2017 INOCA scientific framework formalized this clinical entity: ischemia with no obstructive coronary arteries, encompassing both coronary microvascular dysfunction and epicardial vasospastic disease. (5) It is not a diagnosis of exclusion. It is a distinct pattern of disease with defined diagnostic tools, defined treatments, and prognostic implications that are not benign. Article 7 of this series treats it in depth.

How the Differences Compound

The three biological differences compound. Smaller vessels carry less reserve and are more sensitive to a given plaque burden. Combined with more plaque erosion, acute events more often arise from mechanisms that standard imaging is not optimized to detect. With the more frequent microvascular contribution, a substantial share of cardiac ischemia in women is invisible to the test that has historically served as the gatekeeper for confirming or excluding cardiac disease.

Several syndromes that disproportionately affect women — spontaneous coronary artery dissection and stress (Takotsubo) cardiomyopathy in particular — arise through mechanisms entirely distinct from traditional atherosclerotic plaque, broadening the diagnostic territory further. Article 8 of this series covers these conditions.

Endothelial dysfunction — impaired function of the inner vessel lining — may represent a common thread linking several of these processes. It influences vascular tone, inflammation, thrombosis, and microvascular regulation across atherosclerotic and non-atherosclerotic disease. The diagnostic and treatment frameworks built primarily from male evidence were not built to fail women. They were built to recognize a different pattern. When the disease pattern is broader than the framework, the framework captures less of it.

The Recognition Gap

The biological differences above translate into a clinical pattern documented across multiple registries and emergency department studies. Women are more likely to present with cardiovascular events that fall outside the standard presentation pattern, and more likely to have their symptoms attributed to non-cardiac causes. A broader symptom distribution does not mean women’s symptoms are vague or unreliable. It means the distribution differs from the historical teaching model.

In a National Registry of Myocardial Infarction analysis of more than 1.1 million patients, 42 percent of women presented with confirmed heart attack without chest pain, compared with 31 percent of men. (10) Patients without chest pain were significantly more likely to die during hospitalization, and the absence of chest pain was particularly predictive of mortality in younger women. The absence of chest pain in this dataset does not mean absence of cardiac symptoms — most of these patients had other recognizable presentations: shortness of breath, fatigue, nausea, or discomfort in the jaw, neck, back, or arms.

In a multicenter emergency department study of 10,689 patients with chest pain or symptoms suggestive of acute cardiac ischemia, 2.1 percent of patients with acute heart attack or unstable angina were mistakenly discharged from the emergency department. Patients with acute cardiac ischemia were significantly more likely to be incorrectly discharged if they were women younger than 55, with an adjusted odds ratio of 6.7 (95% CI 1.4 to 32.5). (11) Patients who were incorrectly discharged had significantly higher subsequent mortality than those appropriately hospitalized.

That study is now more than two decades old. Emergency department evaluation pathways have improved substantially since — through high-sensitivity troponin assays, structured decision tools such as the HEART score, and broader clinician awareness. Contemporary registries continue to show that women with cardiac chest pain are less likely to be admitted, less likely to undergo timely catheterization when indicated, and more likely to be diagnosed initially with non-cardiac chest pain when the eventual diagnosis is cardiac. (2)

These findings do not reflect inattentive clinicians. They reflect diagnostic pathways calibrated to a presentation pattern that is incomplete for the population they are being applied to. Article 2 of this series treats heart attack symptoms in women in detail.

Estrogen and the Vascular System

Why do these patterns emerge in women specifically, and what changes when estrogen levels fall? A brief answer here. Articles 5 and 6 of this series treat the menopause transition and hormone therapy in depth.

Estrogen acts on the vascular system through several pathways. It increases production of nitric oxide — a small molecule that signals blood vessels to relax and helps limit inflammation and clotting — through both rapid and longer-term mechanisms. (9) It lowers low-density lipoprotein (LDL) cholesterol, the lipoprotein most strongly associated with cardiovascular risk, and raises high-density lipoprotein (HDL). (9) It influences inflammatory signaling, the behavior of smooth muscle cells in the artery wall, and how the vasculature responds to injury. (9)

These effects help explain the relative cardiovascular protection observed in premenopausal women compared with age-matched men, and the rise in cardiovascular event rates that accompanies the menopause transition.

The cardiovascular protection associated with premenopausal estrogen is relative, not absolute. Women still develop cardiovascular disease before menopause, particularly in the presence of conventional risk factors. The premenopausal advantage is also substantially attenuated by certain conditions — most prominently diabetes, which is associated with a 44 percent greater excess risk of coronary heart disease in women compared with men with diabetes. (12)

And one important framing point: the cardiovascular changes that accompany menopause are not the same as cardiovascular disease being “caused by” menopause. The transition shifts the body into a higher-risk physiologic state. The disease itself reflects cumulative exposure to traditional and sex-specific risk factors across decades.

What Your Care Should Cover

The biological differences this article describes have specific consequences for how a woman should engage with her own cardiovascular health.

Treat symptoms with a lower threshold than the textbook teaches. Chest pain remains the most important cardiac symptom in women. But the symptom range is wider — shortness of breath, fatigue, nausea, jaw or upper-body discomfort, multiple symptoms together. New, persistent, or unexplained cardiovascular symptoms warrant evaluation, not dismissal. Article 2 covers this in detail.

Put your reproductive history in your cardiovascular record. Preeclampsia, gestational hypertension, gestational diabetes, preterm delivery, and premature or surgical menopause are formal cardiovascular risk-enhancing factors in current prevention guidelines. They are not always retrieved automatically decades later. Raising them in your cardiovascular conversations is the action that converts the history into modified care.

Recognize what “normal” tests do and don’t rule out. A normal stress test or normal coronary angiogram reduces the likelihood of obstructive coronary disease but does not necessarily exclude all mechanisms of cardiac ischemia. Microvascular disease, vasospasm, spontaneous coronary artery dissection, heart attack with non-obstructive coronaries, and Takotsubo cardiomyopathy each account for a meaningful share of cardiac events in women. If symptoms persist after a “normal” workup, that is a reason for further conversation, not relief.

Start the cardiovascular conversation in midlife, not later. The menopause transition is when prevention has the most leverage. Routine adult care has historically deferred this conversation; the major societies now argue that it should not. Articles 5 and 6 of this series cover what the midlife and menopausal cardiovascular conversation should include.

Recognize when the standard ten-year risk calculator may understate your risk. Risk-enhancing factors that women carry disproportionately — adverse pregnancy outcomes, premature menopause, autoimmune disease, chronic kidney disease, some inflammatory conditions — are not captured by the standard calculator. Article 10 of this series addresses how the calculator should be modified for women with these factors.

The Bottom Line

Women do not have a different heart. They have differences in how cardiovascular disease develops, presents, and is recognized — and those differences matter. Smaller coronary arteries. A larger share of plaque erosion in fatal heart attacks, particularly in younger women. More frequent microvascular contribution to ischemic disease. Broader presenting symptom patterns. An evidence base built primarily from male research. Diagnostic pathways and prevention frameworks that work well in patients who present like the textbook and less well in patients who don’t.

The field has improved substantially over two decades. The diagnostic frameworks have been updated. The major society scientific statements on women’s cardiovascular health — heart attack symptoms, adverse pregnancy outcomes, menopause, hormone therapy — exist because the gap between the evidence and routine care was real, and the field has formally acknowledged it. The work remaining is closing the gap between what those statements say and what happens in the visits that determine actual care. That work depends substantially on whether women themselves know what to bring to those visits.

The articles that follow build the specifics. Read them as a connected series or jump to the ones that match where you are.

Next: Article 2 covers heart attack symptoms in women — what the data actually show about presentation, why “atypical” is the wrong word for what affects 30 to 40 percent of women with confirmed heart attacks, and when emergency evaluation matters.

Key Terms

Cardiovascular disease (CVD): Diseases of the heart and blood vessels, including coronary heart disease, stroke, heart failure, and peripheral artery disease.

Coronary microvascular dysfunction: Abnormal function of the small coronary blood vessels (arterioles and capillaries) downstream of the larger epicardial coronary arteries imaged on standard angiography. Cannot be diagnosed by routine angiography.

Endothelial nitric oxide synthase (eNOS): The enzyme in vascular endothelial cells that produces nitric oxide, a potent vasodilator with anti-inflammatory and anti-thrombotic effects. Estrogen enhances eNOS activity through multiple mechanisms.

Heart disease: A subset of cardiovascular disease, encompassing coronary heart disease, heart failure, arrhythmias, valvular disease, and other heart-specific conditions. The CDC’s “heart disease” mortality figure (304,970 women in 2023) does not include stroke or hypertensive disease, which would bring the cardiovascular disease total higher.

INOCA: Ischemia with no obstructive coronary arteries. A clinical syndrome of myocardial ischemia in patients whose epicardial coronary arteries on angiography show less than 50 percent stenosis. Most often caused by coronary microvascular dysfunction or epicardial vasospasm.

Lifetime risk: The probability that an individual will develop a specified condition over the remainder of their life from a given starting age. For coronary heart disease beginning at age 40, lifetime risk is approximately 32 percent in women and 49 percent in men.

Plaque erosion: A mechanism of acute coronary thrombosis in which the endothelium overlying a plaque becomes denuded without rupture of the plaque itself. Accounts for a larger share of acute heart attack in women than in men, particularly in younger women.

Plaque rupture: A mechanism of acute coronary thrombosis in which a lipid-rich plaque with a thin fibrous cap fractures, exposing thrombogenic material to circulating blood. The classical mechanism of heart attack and the dominant mechanism in men.

Women’s Ischemia Syndrome Evaluation (WISE): A prospective cohort study sponsored by the National Heart, Lung, and Blood Institute that enrolled 936 women undergoing coronary angiography for suspected ischemia. Established much of the modern evidence base for microvascular disease and non-obstructive coronary artery disease in women.

References

1. Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2026;153(9):e275–e906.
2. Mehta LS, Beckie TM, DeVon HA, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 2016;133(9):916–947.
3. Dodge JT Jr, Brown BG, Bolson EL, Dodge HT. Lumen diameter of normal human coronary arteries: influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation. Circulation. 1992;86(1):232–246.
4. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47(3 Suppl):S21–S29.
5. Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation. 2017;135(11):1075–1092.
6. Scott PE, Unger EF, Jenkins MR, et al. Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol. 2018;71(18):1960–1969.
7. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet.1999;353(9147):89–92.
8. Sheifer SE, Canos MR, Weinfurt KP, et al. Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J. 2000;139(4):649–653.
9. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med.1999;340(23):1801–1811.
10. Canto JG, Rogers WJ, Goldberg RJ, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012;307(8):813–822.
11. Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. 2000;342(16):1163–1170.
12. Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542–1551.